Browse ZNF683

Summary
SymbolZNF683
Namezinc finger protein 683
Aliases MGC33414; Hobit; homolog of Blimp-1 in T cells; hypothetical protein MGC33414
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain -
Function

Transcription factor that mediates a transcriptional program in various innate and adaptive immune tissue-resident lymphocyte T-cell types such as tissue-resident memory T (Trm), natural killer (trNK) and natural killer T (NKT) cells and negatively regulates gene expression of proteins that promote the egress of tissue-resident T-cell populations from non-lymphoid organs. Plays a role in the development, retention and long-term establishment of adaptive and innate tissue-resident lymphocyte T cell types in non-lymphoid organs, such as the skin and gut, but also in other nonbarrier tissues like liver and kidney, and therefore may provide immediate immunological protection against reactivating infections or viral reinfection. Plays also a role in the differentiation of both thymic and peripheral NKT cells. Negatively regulates the accumulation of interferon-gamma (IFN-gamma) in NKT cells at steady state or after antigenic stimulation. Positively regulates granzyme B production in NKT cells after innate stimulation. Associates with the transcriptional repressor PRDM1/BLIMP1 to chromatin at gene promoter regions. ; FUNCTION: Isoform 1: Lacks transcriptional repressor activity. Binds to DNA within promoter regions of the transcriptional repressor PRDM1/BLIMP1 target sites. Unable to regulate interferon-gamma (IFN-gamma) production in cytomegalovirus (CMV)-infected effector CD8(+) T-cells. ; FUNCTION: Isoform 2: Transcriptional repressor that binds to DNA within promoter regions of the transcriptional repressor PRDM1/BLIMP1 target sites. Regulates interferon-gamma (IFN-gamma) production in cytomegalovirus (CMV)-infected effector CD8(+) T cells.

> Gene Ontology
 
Biological Process GO:0001779 natural killer cell differentiation
GO:0001865 NK T cell differentiation
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002323 natural killer cell activation involved in immune response
GO:0002325 natural killer cell differentiation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002521 leukocyte differentiation
GO:0002694 regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0007159 leukocyte cell-cell adhesion
GO:0022407 regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030101 natural killer cell activation
GO:0030217 T cell differentiation
GO:0032814 regulation of natural killer cell activation
GO:0032823 regulation of natural killer cell differentiation
GO:0032826 regulation of natural killer cell differentiation involved in immune response
GO:0033078 extrathymic T cell differentiation
GO:0033082 regulation of extrathymic T cell differentiation
GO:0042110 T cell activation
GO:0045580 regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0051136 regulation of NK T cell differentiation
GO:0051249 regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:1902105 regulation of leukocyte differentiation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903706 regulation of hemopoiesis
Molecular Function GO:0003682 chromatin binding
GO:1990841 promoter-specific chromatin binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolZNF683
Namezinc finger protein 683
Aliases MGC33414; Hobit; homolog of Blimp-1 in T cells; hypothetical protein MGC33414
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ZNF683 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolZNF683
Namezinc finger protein 683
Aliases MGC33414; Hobit; homolog of Blimp-1 in T cells; hypothetical protein MGC33414
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ZNF683 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolZNF683
Namezinc finger protein 683
Aliases MGC33414; Hobit; homolog of Blimp-1 in T cells; hypothetical protein MGC33414
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ZNF683 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.260.411
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1320.804
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3450.449
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1950.842
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4810.775
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.0620.552
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6120.408
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7540.539
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2030.86
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.7710.0128
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0250.0403
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.7590.00517
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ZNF683 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.46.80.61
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolZNF683
Namezinc finger protein 683
Aliases MGC33414; Hobit; homolog of Blimp-1 in T cells; hypothetical protein MGC33414
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ZNF683. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolZNF683
Namezinc finger protein 683
Aliases MGC33414; Hobit; homolog of Blimp-1 in T cells; hypothetical protein MGC33414
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ZNF683. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ZNF683.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolZNF683
Namezinc finger protein 683
Aliases MGC33414; Hobit; homolog of Blimp-1 in T cells; hypothetical protein MGC33414
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ZNF683. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolZNF683
Namezinc finger protein 683
Aliases MGC33414; Hobit; homolog of Blimp-1 in T cells; hypothetical protein MGC33414
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ZNF683 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolZNF683
Namezinc finger protein 683
Aliases MGC33414; Hobit; homolog of Blimp-1 in T cells; hypothetical protein MGC33414
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ZNF683 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolZNF683
Namezinc finger protein 683
Aliases MGC33414; Hobit; homolog of Blimp-1 in T cells; hypothetical protein MGC33414
Chromosomal Location1p36.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ZNF683 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.